NOTE

– Share-Based Compensation

Share-based compensation is recorded in selling and administrative expense in the statements of comprehensive income. The following table details the share-based compensation expense by type of award and the total related tax benefit for the periods presented (in thousands):

	Three Months Ended March 31,
	2020		2019
Stock options and SARs	$	164	$	73
Restricted stock		161		188
Performance shares		74		220
Total share-based compensation expense	$	399	$	481

Related income tax benefit	$	54	$	58

Stock options and SAR

The Company grants stock options and stock-settled SARs to employees that allow them to purchase shares of the Company’s common stock. Stock options are also granted to outside members of the Board of Directors of the Company. The Company determines the fair value of stock options and SARs at the date of grant using the Black-Scholes valuation model.

All stock options and SARs granted prior to

August 3, 2018

vested immediately when granted. Awards issued thereafter vest

two

years after the grant date. Employee awards expire

five

years after the grant date, and those issued to directors expire

ten

years after the grant date. The Company issues new shares upon the exercise of stock options and SARs.

A summary of stock option transactions during the

three

months ended

March 31, 2020

follows:

						Weighted Average
	No. of			Weighted Average		Remaining Life		Aggregate
	Shares			Exercise Price		(in years)		Intrinsic Value
Outstanding, January 1, 2020		701,131		$	16.82		2.95	$	714
Granted(1)		163,545			10.97
Exercised		-			-
Lapsed or cancelled		(97,172	)		18.00
Outstanding, March 31, 2020		767,504			15.42		3.37		217
Exercisable, March 31, 2020		421,123			16.12		2.45		217

(

)

The weighted average grant date fair value of stock options granted was

$2.14

per share.

As of

March 31, 2020

, the Company had

$0.6

million in unrecognized compensation related to nonvested stock options to be recognized over the remaining weighted average vesting period of

1.4

years.

A summary of stock-settled SARs transactions during the

three

months ended

March 31, 2020

follows:

						Weighted Average
	No. of			Weighted Average		Remaining Life		Aggregate
	Shares			Exercise Price		(in years)		Intrinsic Value
Outstanding, January 1, 2020		206,700		$	18.67		2.04	$	-
Granted(1)		153,822			10.97
Exercised		-			-
Lapsed or cancelled		(68,501	)		15.97
Outstanding, March 31, 2020		292,021			15.25		3.41		-
Exercisable, March 31, 2020		126,068			18.95		1.83		-

(

)

The weighted average grant date fair value of SARs granted was

$2.14

per share.

As of

March 31, 2020

, the Company had

$0.3

million in unrecognized compensation related to nonvested SARs to be recognized over the remaining weighted average vesting period of

1.7

years.

Restricted Stock

The Company has granted restricted stock to directors and certain employees which vest at a specified future date, generally after

three

years, or when certain conditions are met. The shares are subject to accelerated vesting under certain circumstances as outlined in the

2013

Incentive Stock and Awards Plan (the

“2013

Plan”). Expense for each of these grants is based on the fair value at the date of the grant and is being recognized on a straight-line basis over the respective service period.

A summary of restricted stock transactions during the

three

months ended

March 31, 2020

follows:

				Weighted Average
	No. of			Grant Date
	Shares			Fair Value
Outstanding, January 1, 2020		151,166		$	18.44
Granted		49,543			10.97
Vested		(34,619	)		16.97
Forfeited		(17,420	)		14.24
Outstanding, March 31, 2020		148,670			16.79

As of

March 31, 2020

, the Company had

$1.5

million of unrecognized compensation cost related to nonvested restricted stock grants expected to be recognized over the remaining weighted average vesting period of

2.1

years.

Performance Shares

Certain employees received service-based or service-based and performance-based shares, to which we collectively refer to as performance shares. The service-based awards vest after the service period is met, which is generally

three

five

years. Expense for these grants is based on the fair value on the date of the grant and is being recognized on a straight-line basis over the respective service period. The performance-based shares generally vest after

five

years if the performance and service targets are met. The Company evaluates the performance conditions associated with these grants each reporting period to determine the expected number of shares to be issued. Expenses for grants of performance shares are recognized on a straight-line basis over the respective service period based on the grant date fair value and expected number of shares to be issued. The awards are subject to accelerated vesting under certain circumstances as outlined in the

2013

Plan.

A summary of performance share transactions during the

three

months ended

March 31, 2020

follows:

				Weighted Average
	No. of			Grant Date
	Shares			Fair Value
Outstanding, January 1, 2020		194,012		$	19.77
Granted		-			-
Vested		(5,892	)		16.97
Forfeited		(8,952	)		20.42
Outstanding, March 31, 2020		179,168			19.83

As of

March 31, 2020

, the Company had

$1.2

million of unrecognized compensation cost related to nonvested performance share grants expected to be recognized over the remaining weighted average service period of

1.4

years.